Figure 5

Scratch (A) and transwell (B) assays following Hilymax-miR-135a, LCL-miR-135a and Anti-EGFR-CIL-miR-135a treatment of GBC-SD cells at 0, 24 and 48 hours. (C) Invasive cell numbers of the Anti-EGFR-CIL-miR-135a group (LCL-miR-135a vs. Anti-EGFR-CIL-miR-135a; **p < 0.01).